POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Seq. Identity (%)	View	Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	1kwm	PROCARBOXYPEPTIDASE B (Homo sapiens)	5 / 12	TRP A  38 ASP A  53 VAL A  52 SER A  50 TYR A 198	None	1.49A	18.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	2f5a	PROTEIN (ANTIBODY 2F5 (HEAVY CHAIN)) (Homo sapiens)	5 / 12	VAL H  34 SER H  30 SER H  55 PHE H  24 ASN H  78	None	1.37A	21.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.06A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  89 ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.95A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  89 ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.71A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	VAL A  87 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.29A	29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	6 / 12	TRP A 109 ASP A 113 SER A 204 SER A 207 ASN A 312 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-3.0A) None	1.31A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 203 SER A 207 PHE A 289 PHE A 290 ASN A 293 ASN A 312 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) None	0.51A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A 117 SER A 207 PHE A 289 ASN A 312 TYR A 316	None ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-3.0A) None	1.34A	42.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3t2n	SERINE PROTEASE HEPSIN (Homo sapiens)	5 / 12	LEU A 199 VAL A 198 ASP A 257 SER A 251 PHE A 246	None	1.41A	21.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 ASP A 113 VAL A 114 PHE A 261 PHE A 262 ASN A 265 ASN A 284 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	0.64A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 203 PHE A 261 PHE A 262 ASN A 284	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.3A)	1.40A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 203 PHE A 261 PHE A 262 ASN A 284 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	0.74A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 203 SER A 207 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.76A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 261 PHE A 262 ASN A 265 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-4.6A)	0.66A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.49A	58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 131 ASP A 135 VAL A 136 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.62A	28.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A1113 SER A1204 SER A1207 ASN A1312 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-2.9A) None	1.23A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	7 / 12	TRP A1109 ASP A1113 VAL A1114 SER A1203 PHE A1290 ASN A1312 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 4.9A) P0G  A1401 (-2.9A) None	1.34A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A1109 ASP A1113 VAL A1114 SER A1203 SER A1207 PHE A1289 PHE A1290 ASN A1293 ASN A1312 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	0.72A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4owt	INTEGRATOR COMPLEX SUBUNIT 3 SOSS COMPLEX SUBUNIT C (Homo sapiens)	5 / 12	LEU A 305 VAL A 217 SER C  79 SER C  80 ASN A 390	None	1.49A	22.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4tpt	LIM DOMAIN KINASE 2 (Homo sapiens)	5 / 12	LEU A 417 VAL A 543 VAL A 467 PHE A 532 PHE A 594	None	1.45A	25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.79A	14.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.05A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.16A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.76A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	VAL A  92 ASP A 115 SER A 196 PHE A 410 PHE A 411	PEG  A1218 ( 4.6A) AQD  A1201 (-3.3A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.08A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	VAL A  92 ASP A 115 SER A 200 PHE A 410 PHE A 411	PEG  A1218 ( 4.6A) AQD  A1201 (-3.3A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.22A	32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	0.68A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) None None	1.10A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.4A) None	1.48A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 VAL A 135 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.79A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  94 ASP A 114 VAL A 115 SER A 197 PHE A 389 PHE A 390 TYR A 416	None 8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.88A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A)	1.09A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.84A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_A_Y00A601_2 (BETA-1 ADRENERGIC RECEPTOR)	2kdk	ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR-LIKE PROTEIN 2 (Homo sapiens)	4 / 4	VAL A 331 PHE A 403 VAL A 372 TRP A 400	None	1.25A	17.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	1kwm	PROCARBOXYPEPTIDASE B (Homo sapiens)	5 / 12	TRP A  38 ASP A  53 VAL A  52 SER A  50 TYR A 198	None	1.49A	18.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	2xyd	ANGIOTENSIN-CONVERTI NG ENZYME (Homo sapiens)	5 / 12	TRP A  40 THR A  44 SER A 123 SER A 119 PHE A 490	None None None None 3ES  A1611 (-4.7A)	1.37A	18.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3p56	RIBONUCLEASE H2 SUBUNIT A (Homo sapiens)	5 / 12	LEU A 100 THR A 120 ASP A 119 SER A 156 TYR A 111	None	1.36A	21.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.09A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  89 ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.93A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  89 ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.72A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A  87 VAL A 111 SER A 196 PHE A 346 TYR A 373	None ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.38A	29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207 PHE A 289 PHE A 290 ASN A 293 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) None	0.56A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 289 PHE A 290 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) None	1.41A	42.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3t2n	SERINE PROTEASE HEPSIN (Homo sapiens)	5 / 12	LEU A 199 VAL A 198 ASP A 257 SER A 251 PHE A 246	None	1.45A	21.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3wge	THIOREDOXIN DOMAIN-CONTAINING PROTEIN 5 (Homo sapiens)	5 / 12	LEU A 286 TRP A 227 VAL A 245 PHE A 268 ASN A 257	None	1.38A	14.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.48A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 PHE A 261 PHE A 262	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A)	1.32A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.70A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 261 PHE A 262 ASN A 265 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-4.6A)	0.63A	58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 131 ASP A 135 VAL A 136 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.67A	28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4iop	C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER A (Homo sapiens)	5 / 12	VAL A 154 TRP A 137 THR A  98 ASP A  97 PHE A  70	None None None NAG  A 201 ( 3.7A) None	1.44A	19.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	7 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 PHE A1290 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 4.9A) None	1.36A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 SER A1207 PHE A1289 PHE A1290 ASN A1293 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) None	0.75A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A1117 SER A1207 PHE A1289 PHE A1290 ASN A1293	P0G  A1401 ( 4.4A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A)	1.35A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4owt	INTEGRATOR COMPLEX SUBUNIT 3 SOSS COMPLEX SUBUNIT C (Homo sapiens)	5 / 12	LEU A 305 VAL A 217 SER C  79 SER C  80 ASN A 390	None	1.44A	22.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4xbr	PROTEIN FAM212A,SERINE/THREO NINE-PROTEIN KINASE PAK 4 (Homo sapiens)	5 / 12	LEU A 456 VAL A 424 ASP A 444 SER A 180 PHE A 516	None	1.29A	22.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4xvm	DNA POLYMERASE NU (Homo sapiens)	5 / 12	LEU A 306 VAL A 305 THR A 224 PHE A 197 ASN A 394	None	1.19A	17.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.82A	14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	5 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) None	1.30A	14.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.03A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.19A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.79A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	VAL A  92 ASP A 115 SER A 196 PHE A 410 PHE A 411	PEG  A1218 ( 4.6A) AQD  A1201 (-3.3A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.14A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	VAL A  92 ASP A 115 SER A 200 PHE A 410 PHE A 411	PEG  A1218 ( 4.6A) AQD  A1201 (-3.3A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.25A	32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.22A	14.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	1.14A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.4A) None	1.50A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 VAL A 135 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.83A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  94 ASP A 114 VAL A 115 SER A 197 PHE A 389 PHE A 390 TYR A 416	None 8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.90A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A)	1.12A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.82A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	1ex0	COAGULATION FACTOR XIII A CHAIN (Homo sapiens)	3 / 3	VAL A 266 ASN A 376 TRP A 375	None	1.00A	16.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	1y4j	SULFATASE MODIFYING FACTOR 2 (Homo sapiens)	3 / 3	VAL A 271 ASN A 186 TRP A 187	None	1.12A	20.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	2gjx	BETA-HEXOSAMINIDASE ALPHA CHAIN (Homo sapiens)	3 / 3	VAL A 512 ASN A 196 TRP A  24	None	1.04A	20.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	2gk1	BETA-HEXOSAMINIDASE SUBUNIT ALPHA (Homo sapiens)	3 / 3	VAL I 512 ASN I 196 TRP A  24	None	1.11A	22.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	3 / 3	VAL A 114 ASN A 312 TRP A 313	ERC  A1201 (-3.8A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A)	1.00A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	3 / 3	VAL A 117 ASN A 312 TRP A 313	None ERC  A1201 (-3.0A) ERC  A1201 (-4.4A)	0.59A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	3 / 3	VAL A 117 ASN A 284 TRP A 285	CAU  A 500 (-4.2A) CAU  A 500 (-3.3A) None	0.65A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	3 / 3	VAL A1114 ASN A1312 TRP A1313	P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A)	1.08A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	3 / 3	VAL A1117 ASN A1312 TRP A1313	P0G  A1401 ( 4.4A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A)	0.97A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	4or2	SOLUBLE CYTOCHROME B562, METABOTROPIC GLUTAMATE RECEPTOR 1 (Escherichia coli; Homo sapiens)	3 / 3	VAL A 721 ASN A 760 TRP A 798	None FM9  A1901 (-3.9A) None	1.04A	23.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	5l46	DIMETHYLGLYCINE DEHYDROGENASE, MITOCHONDRIAL (Homo sapiens)	3 / 3	VAL A 612 ASN A 390 TRP A 392	None	0.50A	17.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	5m8t	5,6-DIHYDROXYINDOLE- 2-CARBOXYLIC ACID OXIDASE (Homo sapiens)	3 / 3	VAL A 333 ASN A 250 TRP A 249	None	0.84A	19.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	5o8f	GAMMA-AMINOBUTYRIC ACID RECEPTOR SUBUNIT BETA-3,GAMMA-AMINOBU TYRIC ACID RECEPTOR SUBUNIT ALPHA-5,GAMMA-AMINOB UTYRIC ACID RECEPTOR SUBUNIT ALPHA-5 (Homo sapiens)	3 / 3	VAL A 241 ASN A 410 TRP A 414	None	1.00A	21.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	5yy8	INFLUENZA VIRUS NS1A-BINDING PROTEIN (Homo sapiens)	3 / 3	VAL A 233 ASN A 277 TRP A 319	None	1.06A	13.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	6d6u	GAMMA-AMINOBUTYRIC ACID RECEPTOR SUBUNIT ALPHA-1,GAMMA-AMINOB UTYRIC ACID RECEPTOR SUBUNIT ALPHA-1 (Homo sapiens)	3 / 3	VAL B 238 ASN B 337 TRP B 341	None	0.98A	13.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	6d6u	GAMMA-AMINOBUTYRIC ACID RECEPTOR SUBUNIT GAMMA-2,GAMMA-AMINOB UTYRIC ACID RECEPTOR SUBUNIT GAMMA-2 (Homo sapiens)	3 / 3	VAL E 248 ASN E 347 TRP E 351	None	0.83A	12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y00_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	6gpl	GDP-MANNOSE 4,6 DEHYDRATASE (Homo sapiens)	3 / 3	VAL B 114 ASN B 208 TRP B 249	F7E  B 402 (-4.1A) F7E  B 402 ( 3.1A) None	1.08A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A 110 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.95A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A  87 SER A 192 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.30A	29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A 109 ASP A 113 PHE A 193 SER A 203 PHE A 289 PHE A 290 ASN A 293 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 (-4.4A) ERC  A1201 (-2.8A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	0.52A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	6 / 12	TRP A 109 ASP A 113 SER A 204 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 ( 4.1A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	1.25A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	7 / 12	TRP A 109 ASP A 113 SER A 207 PHE A 289 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	1.28A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 ASP A 113 PHE A 193 PHE A 261 PHE A 262 ASN A 265 ASN A 284 TRP A 285 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-4.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) None CAU  A 500 (-4.6A)	0.72A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 ASP A 113 PHE A 193 SER A 203 PHE A 261 PHE A 262 ASN A 284 TRP A 285 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-4.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.3A) None CAU  A 500 (-4.6A)	0.84A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 ASP A 113 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.19A	58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 131 ASP A 135 PHE A 340 PHE A 341 ASN A 344 TRP A 367 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) None ERM  A2001 ( 4.8A)	0.63A	28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 131 ASP A 135 SER A 222 TRP A 367 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 ( 4.6A) None ERM  A2001 ( 4.8A)	1.28A	28.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A1109 ASP A1113 PHE A1193 SER A1203 PHE A1289 PHE A1290 ASN A1293 ASN A1312 TRP A1313 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-3.8A) P0G  A1401 (-2.9A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A) None	0.77A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	5 / 12	TRP A1109 ASP A1113 SER A1207 PHE A1289 ASN A1312	None P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 (-2.9A)	1.26A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	7 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TRP A 356 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None None	0.94A	14.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	ASP A 115 SER A 196 PHE A 410 PHE A 411 VAL A 430	AQD  A1201 (-3.3A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.42A	32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 PHE A 327 PHE A 328 ASN A 331 TRP A 355 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None None	0.68A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 ASN A 331 TRP A 355 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) None None None	1.17A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_A_Y00A601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	7 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TRP S 356 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) None EP5  S 401 ( 4.9A)	1.06A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	2xyd	ANGIOTENSIN-CONVERTI NG ENZYME (Homo sapiens)	5 / 12	TRP A  40 THR A  44 SER A 123 SER A 119 PHE A 490	None None None None 3ES  A1611 (-4.7A)	1.38A	18.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.07A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  89 ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.92A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  89 ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	None ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.71A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A  87 VAL A 111 SER A 196 PHE A 346 TYR A 373	None ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.37A	29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	7 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 289 PHE A 290 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) None	1.43A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207 PHE A 289 PHE A 290 ASN A 293 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) None	0.54A	42.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	3t2n	SERINE PROTEASE HEPSIN (Homo sapiens)	5 / 12	LEU A 199 VAL A 198 ASP A 257 SER A 251 PHE A 246	None	1.43A	21.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.48A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 PHE A 261 PHE A 262	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A)	1.28A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.69A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 261 PHE A 262 ASN A 265 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-4.6A)	0.64A	58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 131 ASP A 135 VAL A 136 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.63A	28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4iop	C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER A (Homo sapiens)	5 / 12	VAL A 154 TRP A 137 THR A  98 ASP A  97 PHE A  70	None None None NAG  A 201 ( 3.7A) None	1.43A	19.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A1113 SER A1204 SER A1207 ASN A1293 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) None	1.49A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	7 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 PHE A1290 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 4.9A) None	1.30A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	10 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 SER A1207 PHE A1289 PHE A1290 ASN A1293 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) None	0.74A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A1117 SER A1207 PHE A1289 PHE A1290 ASN A1293	P0G  A1401 ( 4.4A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A)	1.37A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4owt	INTEGRATOR COMPLEX SUBUNIT 3 SOSS COMPLEX SUBUNIT C (Homo sapiens)	5 / 12	LEU A 305 VAL A 217 SER C  79 SER C  80 ASN A 390	None	1.45A	22.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4xbr	PROTEIN FAM212A,SERINE/THREO NINE-PROTEIN KINASE PAK 4 (Homo sapiens)	5 / 12	LEU A 456 VAL A 424 ASP A 444 SER A 180 PHE A 516	None	1.25A	22.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4xvm	DNA POLYMERASE NU (Homo sapiens)	5 / 12	LEU A 306 VAL A 305 THR A 224 PHE A 197 ASN A 394	None	1.17A	17.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	4y2e	DUAL SPECIFICITY PROTEIN PHOSPHATASE 7 (Homo sapiens)	5 / 12	LEU A 229 VAL A 228 THR A 162 ASN A 181 TYR A 194	None	1.28A	20.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.81A	14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	5 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) None	1.25A	14.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.05A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.19A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.78A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	5 / 12	LEU A  90 ASP A 115 VAL A 116 SER A 196 TYR A 438	None AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) None	1.16A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	VAL A  92 ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411	PEG  A1218 ( 4.6A) AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.19A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	VAL A  92 ASP A 115 VAL A 116 SER A 200 PHE A 410 PHE A 411	PEG  A1218 ( 4.6A) AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.18A	32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.22A	14.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	0.74A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) None None	1.14A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.4A) None	1.44A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 VAL A 135 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.78A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	7 / 12	LEU A  94 ASP A 114 VAL A 115 SER A 197 PHE A 389 PHE A 390 TYR A 416	None 8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.93A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.80A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	1.14A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y01_B_Y00B601_2 (BETA-1 ADRENERGIC RECEPTOR)	4idj	FAB HEAVY CHAIN (Homo sapiens)	4 / 4	VAL H  32 VAL H  37 ASN H  35 TRP H  47	None	1.40A	20.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	5 / 12	SER A 204 ASN A 293 ASN A 312 TRP A 313 TYR A 316	ERC  A1201 ( 4.1A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	1.09A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	5 / 12	SER A 204 SER A 207 ASN A 293 ASN A 312 TRP A 313	ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A)	1.44A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 ASN A 293 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	0.76A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207 ASN A 293 ASN A 312 TRP A 313	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A)	0.79A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	1.12A	13.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 TRP A 285 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) None CAU  A 500 (-4.6A)	1.26A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 ASN A 265 ASN A 284 TRP A 285 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) None CAU  A 500 (-4.6A)	0.73A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A)	0.87A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 TRP A 285 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) None CAU  A 500 (-4.6A)	0.76A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 ASN A 265	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.94A	59.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 131 ASP A 135 SER A 222 ASN A 344 TRP A 367 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 ( 4.6A) ERM  A2001 (-4.3A) None ERM  A2001 ( 4.8A)	1.20A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 131 ASP A 135 VAL A 136 ASN A 344 TRP A 367 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 ( 4.8A)	0.54A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	7 / 12	ASP A1113 SER A1204 SER A1207 ASN A1293 ASN A1312 TRP A1313 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A) None	1.15A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	10 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 SER A1207 ASN A1293 ASN A1312 TRP A1313 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A) None	0.47A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	5o9h	C5A ANAPHYLATOXIN CHEMOTACTIC RECEPTOR 1 (Homo sapiens)	5 / 12	VAL A  59 VAL A 248 ASN A 292 ASN A 296 TYR A 300	None OLA  A 417 ( 4.9A) None None None	1.49A	26.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Spodoptera frugiperda; Homo sapiens)	5 / 12	TRP A 125 ASP A 129 SER A 212 TRP A 356 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) None None	0.85A	32.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.09A	20.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 SER A 219 ASN A 331 TRP A 355 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) None None None	0.86A	17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 VAL A 135 TRP A 355 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) None None	0.59A	17.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	ASP A 114 VAL A 115 SER A 193 SER A 197 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.9A)	1.10A	42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	1u3t	ALCOHOL DEHYDROGENASE ALPHA CHAIN (Homo sapiens)	4 / 6	GLY A 175 LEU A 171 PHE A 146 PHE A  21	None	0.99A	12.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	3ohm	1-PHOSPHATIDYLINOSIT OL-4,5-BISPHOSPHATE PHOSPHODIESTERASE BETA-3 (Homo sapiens)	4 / 6	GLY B 301 LEU B 300 PHE B 737 PHE B 179	None	0.74A	7.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	4 / 6	GLY A  90 VAL A 117 PHE A 193 PHE A 290	ERC  A1201 (-3.8A) None ERC  A1201 (-4.4A) ERC  A1201 (-4.8A)	0.63A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	4 / 6	GLY A  90 VAL A 117 PHE A 289 PHE A 290	ERC  A1201 (-3.8A) None ERC  A1201 (-4.5A) ERC  A1201 (-4.8A)	0.49A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4fo0	ACTIN-RELATED PROTEIN 8 (Homo sapiens)	4 / 6	GLY A 109 VAL A 314 PHE A 393 PHE A 544	None None None ATP  A 702 (-4.0A)	1.02A	10.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	4 / 6	GLY A  90 VAL A 117 PHE A 193 PHE A 262	None CAU  A 500 (-4.2A) CAU  A 500 (-4.5A) CAU  A 500 (-4.6A)	0.66A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	4 / 6	GLY A  90 VAL A 117 PHE A 261 PHE A 262	None CAU  A 500 (-4.2A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A)	0.46A	59.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4gnk	1-PHOSPHATIDYLINOSIT OL 4,5-BISPHOSPHATE PHOSPHODIESTERASE BETA-3 (Homo sapiens)	4 / 6	GLY B 301 LEU B 300 PHE B 737 PHE B 179	None	0.72A	4.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4hva	CASPASE-6 (Homo sapiens)	4 / 6	LEU A  74 VAL A 103 PHE A 118 PHE A 143	None	1.04A	22.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	5 / 6	GLY A1090 VAL A1117 PHE A1193 PHE A1289 PHE A1290	None P0G  A1401 ( 4.4A) P0G  A1401 (-3.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A)	0.50A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	4qj4	1-PHOSPHATIDYLINOSIT OL 4,5-BISPHOSPHATE PHOSPHODIESTERASE BETA-3 (Homo sapiens)	4 / 6	GLY B 301 LEU B 300 PHE B 737 PHE B 179	None	0.71A	6.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	5uak	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (Homo sapiens)	4 / 6	GLY A 144 LEU A 145 VAL A  43 PHE A  77	None	0.93A	4.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	5uz7	CALCITONIN RECEPTOR (Homo sapiens)	4 / 6	GLY R 241 LEU R 238 VAL R 320 PHE R 313	None	0.96A	10.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_A_Y00A406_1 (BETA-1 ADRENERGIC RECEPTOR)	6d4j	PROTEIN PATCHED HOMOLOG 1 (Homo sapiens)	4 / 6	GLY A1163 LEU A1162 VAL A 510 PHE A 559	None	0.94A	21.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	5 / 12	SER A 204 ASN A 293 ASN A 312 TRP A 313 TYR A 316	ERC  A1201 ( 4.1A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	1.11A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	5 / 12	SER A 204 SER A 207 ASN A 293 ASN A 312 TRP A 313	ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A)	1.45A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 ASN A 293 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	0.77A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207 ASN A 293 ASN A 312 TRP A 313	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A)	0.79A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 ASN A 312 TRP A 313 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-3.0A) ERC  A1201 (-4.4A) None	1.14A	13.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 TRP A 285 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) None CAU  A 500 (-4.6A)	1.27A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 ASN A 265 ASN A 284 TRP A 285 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) None CAU  A 500 (-4.6A)	0.73A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 207	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A)	0.88A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 TRP A 285 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) None CAU  A 500 (-4.6A)	0.76A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 ASN A 265	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.93A	59.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 131 ASP A 135 SER A 222 ASN A 344 TRP A 367 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 ( 4.6A) ERM  A2001 (-4.3A) None ERM  A2001 ( 4.8A)	1.23A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 131 ASP A 135 VAL A 136 ASN A 344 TRP A 367 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 ( 4.8A)	0.55A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	7 / 12	ASP A1113 SER A1204 SER A1207 ASN A1293 ASN A1312 TRP A1313 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A) None	1.17A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	10 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 SER A1207 ASN A1293 ASN A1312 TRP A1313 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) 1WV  A1403 ( 4.3A) None	0.49A	22.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Spodoptera frugiperda; Homo sapiens)	5 / 12	TRP A 125 ASP A 129 SER A 212 TRP A 356 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) None None	0.85A	32.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.09A	20.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 SER A 219 ASN A 331 TRP A 355 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) None None None	0.87A	17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 VAL A 135 TRP A 355 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) None None	0.59A	17.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	ASP A 114 VAL A 115 SER A 193 SER A 197 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.9A)	1.09A	42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	1u3t	ALCOHOL DEHYDROGENASE ALPHA CHAIN (Homo sapiens)	4 / 6	GLY A 175 LEU A 171 PHE A 146 PHE A  21	None	0.99A	12.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	3ohm	1-PHOSPHATIDYLINOSIT OL-4,5-BISPHOSPHATE PHOSPHODIESTERASE BETA-3 (Homo sapiens)	4 / 6	GLY B 301 LEU B 300 PHE B 737 PHE B 179	None	0.74A	7.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	4 / 6	GLY A  90 VAL A 117 PHE A 193 PHE A 290	ERC  A1201 (-3.8A) None ERC  A1201 (-4.4A) ERC  A1201 (-4.8A)	0.65A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	4 / 6	GLY A  90 VAL A 117 PHE A 289 PHE A 290	ERC  A1201 (-3.8A) None ERC  A1201 (-4.5A) ERC  A1201 (-4.8A)	0.48A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	4fo0	ACTIN-RELATED PROTEIN 8 (Homo sapiens)	4 / 6	GLY A 109 VAL A 314 PHE A 393 PHE A 544	None None None ATP  A 702 (-4.0A)	1.02A	10.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	4 / 6	GLY A  90 VAL A 117 PHE A 193 PHE A 262	None CAU  A 500 (-4.2A) CAU  A 500 (-4.5A) CAU  A 500 (-4.6A)	0.68A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	4 / 6	GLY A  90 VAL A 117 PHE A 261 PHE A 262	None CAU  A 500 (-4.2A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A)	0.46A	59.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	4gnk	1-PHOSPHATIDYLINOSIT OL 4,5-BISPHOSPHATE PHOSPHODIESTERASE BETA-3 (Homo sapiens)	4 / 6	GLY B 301 LEU B 300 PHE B 737 PHE B 179	None	0.72A	4.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	5 / 6	GLY A1090 VAL A1117 PHE A1193 PHE A1289 PHE A1290	None P0G  A1401 ( 4.4A) P0G  A1401 (-3.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A)	0.53A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	4qj4	1-PHOSPHATIDYLINOSIT OL 4,5-BISPHOSPHATE PHOSPHODIESTERASE BETA-3 (Homo sapiens)	4 / 6	GLY B 301 LEU B 300 PHE B 737 PHE B 179	None	0.71A	6.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	5uak	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (Homo sapiens)	4 / 6	GLY A 144 LEU A 145 VAL A  43 PHE A  77	None	0.92A	4.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	5uz7	CALCITONIN RECEPTOR (Homo sapiens)	4 / 6	GLY R 241 LEU R 238 VAL R 320 PHE R 313	None	0.95A	10.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7L_B_Y00B405_1 (BETA-1 ADRENERGIC RECEPTOR)	6d4j	PROTEIN PATCHED HOMOLOG 1 (Homo sapiens)	4 / 6	GLY A1163 LEU A1162 VAL A 510 PHE A 559	None	0.94A	21.35